Liquidia Technologies is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics.
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 13, 2021 | Post-IPO Equity | $21.70M | 1 | Caligan Partners | — | Detail |
Dec 26, 2019 | Post-IPO Equity | $22.40M | 2 | — | — | Detail |
Jun 14, 2006 | Series A | $6M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Caligan Partners | Yes | Post-IPO Equity |
BKB Growth Investments | — | Post-IPO Equity |
AMDG 1 | — | Post-IPO Equity |
Siemens AG | — | Series A |